CBD for Recurrent Pericarditis: Why a Promising Pilot Still Needs a Comparator
Pain and inflammatory-marker improvements in a CBD pericarditis pilot are encouraging observations, but the trial cannot establish how much improvement CBD caused. It enrolled a small group, used no placebo arm and initially continued background treatment.
Who received what treatment?
This phase II study enrolled 27 adults with symptomatic recurrent pericarditis at eight US centers. Participants received a manufactured oral CBD solution, titrated as tolerated up to 10 mg/kg twice daily. THC was not detected in the formulation at the stated analytical limit; that is a product-specific result.
Background nonsteroidal anti-inflammatory drugs, colchicine and/or corticosteroids remained unchanged during the first eight weeks. An optional 18-week extension allowed background-therapy weaning. This was an open-label, single-arm human trial, not a randomized comparison of CBD against those established treatments.
What improved?
The mean maximal numerical pain rating decreased from 5.8 at baseline to 2.1 at week eight. Of the ten participants with elevated baseline C-reactive protein, eight had normalization at week eight. During the extension, 17 of 24 participants remained free of a new recurrence.
These outcomes are not interchangeable. Pain is patient-reported, C-reactive protein is a systemic inflammatory marker, and recurrence is a clinical event. The eight-person normalization result also refers to the ten-person elevated-marker subgroup, not all 27 enrolled patients.
Why before-and-after comparisons cannot isolate CBD
Patients entered while symptomatic, so natural fluctuation and regression toward a less severe state are relevant alternatives. Continued medicines, close clinical follow-up and later changes in background treatment also complicate attribution.
The reported reduction in recurrence rate relative to the patients’ prior history is not a randomized comparison with an untreated contemporaneous group. Comparisons with separate trials of other drugs cannot establish equivalent efficacy because enrollment and treatment conditions differ.
Tolerability needs the same context
Diarrhea occurred in 15 participants and rash in eight. The report describes a serious hypersensitivity-type event considered possibly related to study medication in a patient also newly receiving celecoxib. The concurrent medication and clinical history prevent a simple single-cause conclusion.
The trial was funded by the product developer, and the authors report relevant relationships. Its small sample, short extension and lack of a comparator constrain both efficacy and safety conclusions. The appropriate next step in the evidence is a larger controlled trial, rather than treating this pilot as proof that a retail CBD product can replace pericarditis care.
Related analysis: Adult Epilepsy CBD Outcomes: Treatment Retention and Confounding Matter.
Primary research
Sushil Allen Luis and colleagues. Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (2026). DOI: 10.1161/JAHA.125.047605.
